News - Bexsero, Ryzodeg


Current filters:


Popular Filters

Novo Nordisk accused of delaying information release under Danish STC rules

Novo Nordisk accused of delaying information release under Danish STC rules


Danish insulin giant Novo Nordisk revealed this morning that the Danish Financial Supervisory Authority…

DenmarkDiabetesEuropeFinancialLegalNovo NordiskPharmaceuticalRyzodegTresiba

BNDES invests 804 million real in Novartis' new Brazil biotechnology unit

BNDES invests 804 million real in Novartis' new Brazil biotechnology unit


The Brazilian Development Bank will finance 804 million real ($342 million) for the construction of a…

BexseroBiotechnologyBrazilFinancialNovartisProductionSouth AmericaVaccines

Novartis MenB vaccine approved in Australia


Swiss drug major Novartis (NOVN: VX) revealed this morning (August 15) that the Australian Therapeutic…


Disappointment for Novartis over rejection of meningitis vaccine in the UK


The UK Joint Committee on Vaccination and Immunization (JCVI) will not recommend meningitis vaccine Bexsero…


Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg


Danish insulin giant Novo Nordisk (NOV: N) revealed late Sunday that, on February 8, it received a Complete…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

EU approval for Novo Nordisk's Tresiba and Ryzodeg and for Novartis' for Bexsero


Following positive recommendations from the European Medicines Agency's advisory committee, the European…

BexseroDiabetesEuropeNovartisNovo NordiskPharmaceuticalRegulationRyzodegTresibaVaccines

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review


Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene


There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…


FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg


US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

FDA briefing papers for Novo Nordisk's insulin degludec note need to review cardiac risks


The US Food and Drug Administration yesterday published the briefing documents ahead of the Advisory…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk says US FDA advisory panel to focus on degludec cardiovascular safety


Denmark-based insulin giant Novo Nordisk (NOV: N) late yesterday announced that the US Food and Drug…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

EMA panel backing for Novo Nordisk's Tresiba and Ryzodeg: Japanese review


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday announced…

Asia-PacificDegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulationRyzodegTresiba

FDA further delays Novo Nordisk's ultra long-acting insulin products Tresiba and Ryzodeg


Denmark's Novo Nordisk (NOV: N), the world's largest insulin maker, says that the US Food and Drug Administration…

DiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk starts year with 15% net profits hike


Danish insulin giant Novo Nordisk (NOV: N) reported first-quarter 2012 results last Friday, with a 13%…

DegludecDiabetesFinancialNovo NordiskPharmaceuticalRyzodegTresiba

Novartis says Bexsero shows significant potential against meningococcal serogroup B infections


Swiss drug major Novartis (NVN: VX) says that new data from a pivotal study in more than 1,800 infants…

Antibiotics and Infectious diseasesBexseroNovartisPharmaceuticalResearchVaccines

Back to top